Core Viewpoint - BeyondSpring Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC, which includes the company's audited consolidated financial statements [1]. Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for high unmet medical needs [3]. - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer (NSCLC) and other indications [3]. - Plinabulin operates through a novel mechanism as a dendritic cell maturation agent, which supports anti-cancer activity and immune modulation, providing a unique approach to enhancing tumor sensitivity to checkpoint inhibitors [3]. Financial Reporting - The annual report on Form 10-K can be accessed on the SEC's website and the company's website under the "Latest Results" section in the Investors area [1]. - The company offers a hard copy of its annual report containing audited consolidated financial statements free of charge to shareholders upon request [2].

Core Viewpoint - FibroBiologics, Inc. has announced a 1-for-20 reverse stock split to comply with Nasdaq listing requirements and attract broader investor interest, effective March 30, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from 70,256,883 to approximately 3,512,845 shares [1]. - The reverse stock split was approved by stockholders on February 20, 2026, allowing the Board of Directors to implement it [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share [3]. Group 2: Impact on Shareholders - The reverse stock split will not alter any stockholder's percentage ownership interest in the company, except for adjustments related to fractional shares [3]. - The number of shares available under the company's equity incentive plans and the exercise price of outstanding stock options will be proportionately adjusted [3]. Group 3: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [5]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer [5].

Core Viewpoint - Northland Power Inc. has appointed Bahir Manios to its Board of Directors, expanding the Board from ten to eleven members, effective March 25, 2026 [1] Group 1: Appointment Details - Bahir Manios brings over 20 years of senior leadership experience in asset management and extensive North American capital markets experience to Northland's Board [2] - Mr. Manios is the co-founder of Genesis Financial Asset Management, which invests in Healthcare, Infrastructure, and Financial Services sectors [2] - He previously held senior executive positions at Brookfield Asset Management, including Chief Financial Officer, and played a key role in developing Brookfield's infrastructure business [2] Group 2: Company Overview - Northland Power is a Canadian-owned global power producer focused on accelerating the global energy transition, with a history dating back to 1987 [4] - The company develops, owns, and operates a diversified mix of energy infrastructure assets, including offshore and onshore wind, solar, battery energy storage, and natural gas [4] - Northland has a gross operating generating capacity of 3.5 GW, with 2.2 GW under construction and approximately 9 GW of potential capacity in early to mid-stage development [5]

Core Insights - Planet 13 Holdings Inc. reported its financial results for Q4 and the full year 2025, indicating a stabilization in revenue and a focus on improving operational efficiency [1][2][3]. Financial Highlights - Q4 2025 - Q4 2025 revenue was $25.2 million, a decrease of 16.7% compared to $30.3 million in Q4 2024, attributed to the tourist environment in Las Vegas and competition in Florida [5][6]. - The net loss for Q4 2025 was $4.6 million, significantly improved from a net loss of $26.4 million in Q4 2024, which included an impairment of $18.9 million [6][10]. - Adjusted EBITDA loss was $0.3 million, compared to an Adjusted EBITDA of $0.0 million in Q4 2024, marking a substantial improvement [6][10]. Financial Highlights - Full Year 2025 - Total revenue for 2025 was $103.4 million, down 11.2% from $116.4 million in 2024, again due to the tourist environment and competition [7][10]. - Gross profit for the year was $39.9 million, representing a gross margin of 38.6%, down from 48.2% in 2024, primarily due to weaker flower quality and increased competition [7][10]. - The net loss for the full year was $63.9 million, compared to a net loss of $47.8 million in 2024, which included $29.8 million in non-cash impairment charges [7][10]. Balance Sheet Overview - As of December 31, 2025, cash and restricted cash totaled $15.6 million, down from $25.4 million in 2024 [12]. - Total assets decreased to $152.3 million from $206.7 million, while total liabilities increased to $101.2 million from $94.0 million [12][20]. Recent Developments - The company announced the opening of new dispensaries in Florida and a complete exit from California, which is expected to enhance operational focus and efficiency [13][3]. - A new rewards program was launched in February 2026, aimed at improving customer engagement and retention [13]. Management Commentary - Co-CEOs expressed optimism about the operational and regulatory environment aligning with the company's strategy, emphasizing the goal of achieving cash flow positivity in 2026 [2][3].

Core Insights - Serina Therapeutics, Inc. reported significant advancements in its clinical programs and financial position, particularly with the FDA clearance of SER-252 for advanced Parkinson's disease and securing up to $30 million in financing [2][7]. Financial Performance - Operating expenses for 2025 were $24.2 million, an increase from $17.1 million in 2024 [4]. - Research and Development (R&D) expenses rose to $13.2 million in 2025 from $7.5 million in 2024, primarily due to increased clinical activities and headcount [5]. - General and Administrative expenses increased to $11.0 million in 2025 from $9.6 million in 2024, driven by stock-based compensation and consulting expenses [6][8]. - The net loss attributable to Serina common stockholders for 2025 was $19.4 million, or $(1.91) per share, compared to a net loss of $11.1 million, or $(1.51) per share in 2024 [10][23]. Liquidity and Financing - As of December 31, 2025, cash and cash equivalents totaled $3.1 million [11]. - The company secured $16.0 million in gross proceeds from a private placement financing, with potential additional proceeds from warrant exercises [7]. - An At-the-Market (ATM) equity program raised $10.0 million in 2026 from the sale of 3.0 million shares [7]. Recent Business Highlights - The FDA granted IND clearance for SER-252, and the first patient was dosed in the Phase 1 registrational trial in February 2026 [7]. - The company has a strategic partnership with Pfizer for the use of its POZ polymer technology in drug delivery formulations [14]. Product Pipeline - SER-252 is designed to provide continuous dopaminergic stimulation for Parkinson's disease, with preclinical studies indicating potential benefits without skin reactions [15]. - SER-270, another investigational product, aims to address adherence challenges in tardive dyskinesia and is also being explored for Huntington's disease [17].

Financial Overview - The company reported a cash position of $3.7 million as of December 31, 2025, down from $12.5 million as of December 31, 2024, indicating potential liquidity issues for the next 12 months [2] - The net loss for the year ended December 31, 2025, was $4.9 million, a decrease from a net loss of $9.7 million in 2024, primarily due to a $6.0 million gain from lease liability reversal [7] Research and Development - Research and development expenses increased to $3.3 million for the year ended December 31, 2025, compared to $0 in 2024, reflecting activities following the acquisition of GPCR Therapeutics USA Inc. [3] General and Administrative Expenses - General and administrative expenses rose to $6.8 million in 2025 from $5.4 million in 2024, driven by costs associated with the acquisition and integration of GPCR USA [4] Other Income and Expenses - The company recognized a $6.0 million gain from the early termination of its lease in Chicago, effective January 31, 2025 [5] - Other income included a $346,000 gain in Q3 2025 from satisfying self-insured retention, but there were losses totaling $1,553,000 related to changes in fair value of contingent liabilities and $275,000 from the sale of its subsidiary, KC Creation [6] Balance Sheet Highlights - Total assets decreased to $14.0 million as of December 31, 2025, from $15.1 million in 2024, with current assets also declining significantly [13][14] - Total liabilities increased to $10.1 million in 2025 from $8.3 million in 2024, with a notable rise in accounts payable and contingent consideration [13][14] Company Background - Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies. Following a restructuring, the company is exploring strategic alternatives to maximize stockholder value and has acquired a clinical-stage biotechnology company [9]

Group 1 - Colombier Acquisition Corp. III announced that starting March 27, 2026, holders of units from its initial public offering can separately trade Class A ordinary shares and warrants [1] - The Class A ordinary shares will trade under the symbol "CLBR" and the warrants under "CLBR WS" on the New York Stock Exchange, while units that are not separated will continue to trade under "CLBR U" [1] - The company is a blank check company formed to effect a merger or similar business combination, with a focus on industries where its management team has expertise [2] Group 2 - The press release includes forward-looking statements regarding potential business combinations and financing, which are based on management's beliefs and assumptions [3] - Actual results may differ from these forward-looking statements due to various factors beyond the company's control [3]

Core Insights - Caliber establishes guidance for 2026 with expected revenue between $18 million and $22 million, anticipating positive net operating income and adjusted EBITDA profitability [1][9][10] Financial Performance - For Q4 2025, platform revenue was $4.0 million, down from $4.6 million in Q4 2024, primarily due to timing of development and financing activities [7][22] - Full year 2025 platform revenue totaled $15.2 million, compared to $20.9 million in 2024, reflecting delays in capital markets activity [7][22] - The platform net loss for Q4 2025 was $7.7 million, or $1.24 per diluted share, an improvement from a net loss of $11.6 million, or $10.34 per diluted share in Q4 2024 [7][22] - For the full year 2025, the platform net loss was $21.2 million, or $7.50 per diluted share, compared to a net loss of $19.6 million, or $17.86 per diluted share in 2024 [7][22] Asset Management and Capital - Fair value assets under management (FV AUM) decreased by 1.9% to $779.7 million as of December 31, 2025, due to the disposition of three hospitality assets [7][22] - Managed capital increased by 5.0% to $517.2 million, with originations of $26.5 million [7][22] - The company staked 75,000 LINK tokens valued at $6.9 million and began tokenizing two real estate projects to enhance investor liquidity and fundraising capabilities [7][8] Strategic Outlook - Management believes that the anticipated conversion of the existing project pipeline into realized revenue will drive profitability in 2026 [8][10] - Approximately 60% of the anticipated revenue growth in 2026 is expected to come from debt financing-related activities, with the remaining 40% from capital formation and asset management activities [9][10]

Core Viewpoint - ARMOUR Residential REIT, Inc. has announced a cash dividend of $0.24 per Common share for April 2026, reflecting its ongoing commitment to return value to shareholders [1]. Dividend Information - The dividend of $0.24 will be payable to shareholders of record as of April 15, 2026, with a payment date set for April 29, 2026 [2]. Tax Matters - ARMOUR is taxed as a real estate investment trust (REIT) and must distribute substantially all of its ordinary REIT taxable income to maintain this status. Dividends exceeding current tax earnings and profits are generally not taxable to common stockholders. The actual dividends are determined by the Company's board, considering various factors such as operational results, cash flows, financial condition, and market conditions [3]. Company Overview - ARMOUR primarily invests in fixed-rate residential, adjustable-rate, and hybrid adjustable-rate residential mortgage-backed securities that are issued or guaranteed by U.S. Government-sponsored enterprises or the Government National Mortgage Association. The Company is externally managed by ARMOUR Capital Management LP, which is registered with the SEC [4].

Core Points - ONEOK, Inc. announced the retirement of directors Gerald B. Smith and Pattye L. Moore from its board effective May 20, 2026, coinciding with the company's Annual Meeting of Shareholders [1] - Smith's retirement aligns with ONEOK's mandatory director retirement age policy, while Moore has chosen to retire [1] - Smith has been on the board since 2020 and is the founder and former CEO of Smith, Graham & Company Investment Advisors [2] - Moore has served on the board since 2002 and is the former chairman of Red Robin Gourmet Burgers and former president of Sonic Corp [3] - The management team expressed gratitude for the contributions and guidance provided by both directors during their tenure, which has significantly shaped ONEOK's development into a leading midstream infrastructure company [4] Company Overview - ONEOK is a leading midstream operator that provides essential energy products and services, including gathering, processing, fractionation, transportation, storage, and marine export services [4] - The company operates an extensive pipeline network of approximately 60,000 miles, transporting natural gas, natural gas liquids, refined products, and crude oil to meet energy demand [4] - As one of the largest integrated energy infrastructure companies in North America, ONEOK plays a crucial role in energy security and delivering reliable energy solutions [4]